Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464657 | 0.98 | SLC2A1 (0.36) | SLC2A1NR1I2ACACBOPRM1MAPT | |
| SCHEMBL19232032 | 0.95 | SLC2A1 (0.35) | SLC2A1NR1I2ACACBOPRM1MAPT | |
| SCHEMBL24804934 | 0.92 | NR1I2 (0.43) | SLC2A1NR1I2ACACBOPRM1MAPT | |
| SCHEMBL19464598 | 0.92 | NR1I2 (0.43) | SLC2A1NR1I2ACACBOPRM1MAPT | |
| SCHEMBL19987499 | 0.88 | NR1I2 (0.36) | NR1I2ACACB | |
| SCHEMBL19987473 | 0.87 | ITGB3 (0.38) | SLC2A1NR1I2DNM1 | |
| SCHEMBL19987455 | 0.87 | ITGB3 (0.38) | SLC2A1NR1I2DNM1 | |
| SCHEMBL19231976 | 0.85 | ITGB3 (0.39) | SLC2A1NR1I2 | |
| SCHEMBL19231975 | 0.85 | ITGB3 (0.39) | SLC2A1NR1I2 | |
| SCHEMBL19231971 | 0.83 | SLC2A1 (0.36) | SLC2A1ACACBOPRM1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | SLC2A1 1906/4885NR1I2 1266/4885DNM1 3021/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | SLC2A1 1906/4885NR1I2 1266/4885DNM1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.